|
|
News for Healthier Living
Daraxonrasib Demonstrates Initial Antitumor Activity in RAS-Mutant Lung Cancer
Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.
September 2, 2026
September 8 2026September 7 2026September 5 2026September 4 2026September 3 2026September 2 2026September 1 2026August 31 2026August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026
|
|
|
|
|